Total
0
Shares
Epsilon Healthcare’s (ASX:EPN) Tetra Health launches face-to-face clinic
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cann Global (CGB) has entered a binding agreement with Western Sydney University’s NICM Health Research Institute
  • The company is currently evaluating the efficacy of a unique strain of medicinal cannabis to slow the progression of multiple sclerosis (MS)
  • Under the agreement, the parties will design a clinical trial protocol for the purpose of undertaking human clinical trials in Australia
  • On the market today, Cann is up 21.4 per cent and is trading at 0.9 cents per share

Cann Global (CGB) has entered a binding agreement with Western Sydney University’s NICM Health Research Institute.

The company is currently evaluating the efficacy of a unique strain of medicinal cannabis to slow the progression of multiple sclerosis (MS).

Under the agreement, the parties will design a clinical trial protocol for the purpose of undertaking human clinical trials in Australia.

Last year, Cann saw successful research results in Israel, where research led by Dr Dedi Meiri found that a unique cannabis strain in mice trials stopped the progression of MS and, in some cases, significantly reversed the damage caused by MS.

In February, Cann Global announced that the human clinical trials for this research would be continued in Australia, as clinical data and results are recognised worldwide due to the high standard of research.

NICM Health Research Institute is Australia’s leader in integrative and complementary medicine research and policy.

"Cann will update the market with the expected timetable for implementation
of the clinical trials once the protocol has been designed," Cann told the market today.

On the market today, Cann is up 21.4 per cent and is trading at 0.9 cents per share at 11:27 am AEST.

CGB by the numbers
More From The Market Herald
Telix Pharmaceuticals (ASX:TLX) - CEO, Dr. Christian Behrenbruch - The Market Herald

" TGA fast tracks evaluation of Telix Pharmaceuticals’ (ASX:TLX) cancer imaging product

The Theraputic Goods Administration (TGA) has commenced a priority evaluation process for Telix Pharmaceuticals’ (TLX) prostate cancer imaging product, Illuccix.
Pharmaxis (ASX:PXS) - CEO, Gary Phillips (left) - The Market Herald

" Pharmaxis (ASX:PXS) to raise $4.4M via placement

Pharmaxis (PXS) has received firm commitments to raise $4.4 million through a placement.
Universal Biosensors (ASX:UBI) - CEO, John Sharman - The Market Herald

" Universal Biosensors (ASX:UBI) toasts new distribution agreement for wine testing device

Universal Biosensors (UBI) has entered into a non-exclusive agreement with Singularity SpA to distribute its wine testing platform device in Chile.
Paradigm Biopharmaceuticals (ASX:PAR) - Chairman & CEO, Paul Rennie - The Market Herald

" Paradigm Biopharmaceuticals (ASX:PAR) enrols first participant in osteoarthritis trial

Paradigm Biopharmaceuticals (PAR) has enrolled its first patient in its knee osteoarthritis (OA) biomarker study in Box Hill, Victoria.